Enovis Corporation (ENOV) 株式分析

企業概要

Enovis Corporation is a medical technology enterprise that develops and provides clinically differentiated solutions for the orthopedic market both within the United States and internationally. The company operates primarily within the Healthcare sector, specifically specializing in the Medical Devices industry, which encompasses the design, manufacture, and distribution of instruments and implants for surgical procedures. This organization employs a workforce of 7,802 individuals and maintains a total market capitalization of $1.38B, reflecting its position as a mid-to-large-cap entity in the specialized medical supply chain. Its annual revenue generation reaches $2.25B, a figure that indicates a substantial operational footprint and significant scale relative to smaller niche competitors, positioning it as a major player in the prevention, recovery, and reconstructive segments of orthopedics.

財務健全性

Enovis Corporation reported a trailing twelve-month revenue of $2.25B, yet recorded a net income of -$1,182,530,944, highlighting a severe divergence between top-line sales and bottom-line profitability that points to substantial cost pressures or one-time expenses. Despite the negative net income, the company generated an EBITDA of $369.17M, suggesting that core operational cash generation remains positive even after accounting for significant non-operating losses or extraordinary charges. The business also produced free cash flow of $104.43M, which provides a critical buffer for financial flexibility, allowing the company to fund operations or debt service despite reported accounting losses. Profitability analysis reveals a gross margin of 60.9%, indicating efficient production and pricing power for its devices, while an operating margin of 6.1% suggests that overhead costs are consuming a notable portion of revenue. However, the profit margin stands at -52.7%, confirming that the bottom line is heavily impacted by factors beyond core operations, such as interest expenses or restructuring costs. On the balance sheet side, the company holds cash totaling $36.39M against total debt of $1.38B, resulting in a debt-to-equity ratio of 92.47, which characterizes a highly leveraged capital structure with limited equity cushion. The current ratio of 2.02 indicates that current assets are more than double current liabilities, suggesting adequate short-term liquidity to meet obligations as they come due. Return on Equity is calculated at -58.3%, signaling that shareholders are experiencing a decline in book value, while Return on Assets sits at 1.1%, reflecting minimal efficiency in generating profit from the asset base.

バリュエーション評価

The valuation metrics for Enovis show a trailing P/E ratio marked as N/A due to negative earnings, while the forward P/E is projected at 6.05, implying that the market expects a significant turnaround in earnings trajectory to justify any trailing multiple. The price-to-book ratio is recorded at 0.92, indicating that the market values the company at less than its tangible book value, which often suggests a deep discount or market skepticism regarding future asset utilization. Alternative valuation measures include a price-to-sales ratio of 0.61 and an EV/EBITDA of 7.37, metrics that suggest the stock is priced conservatively relative to its sales volume and enterprise earnings before interest, taxes, depreciation, and amortization. In terms of trading range, the stock has a 52-week high of $37.85 and a 52-week low of $21.00; without the current specific share price, the exact percentage deviation cannot be calculated, but the range defines the volatility band within which the security has traded over the last year. The beta value is 1.59, which indicates that the stock price is expected to be 59% more volatile than the broader market, reflecting higher systematic risk associated with the specific dynamics of the medical device sector and this company's operational profile.

Growth & Income

Enovis Corporation demonstrates a year-over-year revenue growth of 2.6%, whereas earnings growth is listed as N/A due to the reported net loss, implying that top-line expansion has not yet translated into bottom-line accretion. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated earnings are retained for reinvestment into growth initiatives rather than being distributed to shareholders. The absence of a dividend payout suggests a strategy focused on capitalizing on future market share gains and operational improvements to restore profitability before initiating any shareholder returns. Overall, the company presents a growth and income profile characterized by moderate revenue expansion and a complete absence of current dividend income, relying instead on potential future earnings recovery to alter its capital allocation strategy.